Sbarouni Eftihia, Kyriakides Zenon S, Kremastinos Dimitrios Th
2nd Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.
Am J Cardiol. 2004 Jan 15;93(2):217-8. doi: 10.1016/j.amjcard.2003.09.043.
Because statins seem to attenuate the early, increased cardiovascular hazard induced by hormone replacement therapy (HRT), we treated 16 postmenopausal hypercholesterolemic women with coronary artery disease with combined HRT, simvastatin, and the combination of HRT and simvastatin in a double-blind, crossover, placebo-controlled study; we also evaluated C-reactive protein (CRP) levels at the end of each treatment period. We found that only HRT significantly increased CRP compared with placebo, whereas the combination of HRT with simvastatin did not. We concluded that statins may reduce the inflammatory adverse effects associated with the CRP increase induced by HRT.
由于他汀类药物似乎能减轻激素替代疗法（HRT）引发的早期心血管风险增加，我们在一项双盲、交叉、安慰剂对照研究中，对16名患有冠状动脉疾病的绝经后高胆固醇血症女性进行了联合HRT、辛伐他汀以及HRT与辛伐他汀联合治疗；我们还在每个治疗期结束时评估了C反应蛋白（CRP）水平。我们发现，与安慰剂相比，只有HRT显著增加了CRP，而HRT与辛伐他汀联合使用则没有。我们得出结论，他汀类药物可能会减少与HRT诱导的CRP增加相关的炎症不良反应。
